CA-TTTECH-INDUSTRIAL
25.5.2021 10:02:06 CEST | Business Wire | Press release
TTTech Industrial Automation AG has acquired core technology and strategic customers from pioneering fog/edge computing start-up Nebbiolo Technologies in a deal closed in May. Integrating features and know-how from Nebbiolo Technologies will support TTTech Industrial’s commitment to delivering the world’s most advanced industrial edge computing platform to its customers. TTTech Industrial has also founded a US subsidiary in Silicon Valley to expand its activities in the North American market. Kannan Devarajan, one of the co-founders of Nebbiolo Technologies has joined TTTech Industrial North America Inc. as Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005037/en/
TTTech Industrial is a leading provider of industrial IoT solutions, and partners with key players in IoT such as Intel and Microsoft. The company’s Nerve software platform has been at the forefront of industrial edge computing since its launch in 2016. The foundation of TTTech Industrial North America supports the expansion of commercial operations in the US and Canada, with the technology and customer assets acquired from Nebbiolo Technologies forming the nucleus of these activities.
Nebbiolo Technologies is renowned as the pioneer of fog computing, with patented technology that is foundational to industrial edge computing concepts. The company was named a Gartner Cool Vendor in 2017 and was recognized as the Customer Value Leader in the IIoT edge computing market by Frost & Sullivan in 2019. The combination of existing Nerve product features with Nebbiolo Technologies’ expertise will provide customers with an unparalleled solution for software management at the edge, remote connectivity, edge analytics, high-availability, and security.
TTTech Industrial has an existing customer base of machine builders and system integrators based in Europe, the US and Asia. Aside from growing its operations in North America and Asia, this deal also allows TTTech Industrial to widen the scope of its activities to new industries such as energy, oil/gas and auto manufacturing, strengthen the global reach of its edge computing solutions and bolster go-to-market activities in Europe.
"The launch of our US subsidiary marks a significant step for our company. Our location in Silicon Valley brings us closer to customers and allows us to tap into a pool of the world's best software engineering talent. The integration of assets from Nebbiolo Technologies enables us to offer even more advanced industrial edge computing solutions to new and existing customers in a wider range of application fields,” explains Thomas Berndorfer, Member of the Executive Board, TTTech Industrial Automation AG.
“I am very proud to be leading TTTech Industrial's expansion into North America. My team and I bring a wealth of experience in edge computing solutions that will contribute to making Nerve the platform of choice for industrial automation customers. In addition, we will provide customers with expert local sales and technical support, as well as custom feature development," says Kannan Devarajan, Managing Director, TTTech Industrial North America.
CEO and co-founder of Nebbiolo Technologies Chandra Joshi states, “We have been partnering with TTTech Industrial from the outset of our journey. I am confident that the integration of Nebbiolo’s technology with TTTech Industrial’s Nerve product line will create a leading-edge computing platform to enable existing and new customers to accelerate their digital transformation.”
About TTTech Industrial Automation AG
TTTech Industrial aspires to unlock the incredible potential of industrial automation. It combines transformative technologies with hands-on experience in critical real-time systems to offer customers flexibility, reliability and choice. TTTech Industrial operates under the umbrella of the TTTech Group, a leading provider of safe networked computing platforms, with cross-industry experience from more than 20 years of operation.
TTTech Industrial product lines Nerve, Slate and Flexibilis are designed to converge and connect automation systems. Nerve is a flexible, open industrial edge computing platform that enables users to access data, manage devices and deploy applications remotely. Slate is a deterministic networking platform that provides comprehensive TSN solutions. Flexibilis is a redundant networking product portfolio that delivers high-availability seamless redundancy for a wide range of industrial applications, most notably in the energy industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom